UNSPSC 51312205: Rupatadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H26ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AE8M83G3E, chemically known as 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but generally known as rupatadine, which bears US NIH Compound Identifier 133017. European Medicines Agency schedules Rupatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10406MIG.

UNSPSC 51312205 Rupatadine is a Commodity code that nominally names a specific antihistamine product, but recent state and local activity under this code does not align with that narrow pharmaceutical scope. The three most recent opportunities—a Seminole County naloxone procurement, a Texas Health and Human Services Commission RFI on direct-to-manufacturer pharmacy programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—reflect broader pharmaceutical procurement, inventory management, and pharmacy benefit administration rather than procurement of rupatadine itself. State and local buyers posting under this code span county health departments, state health agencies, and cooperative purchasing organizations serving multiple jurisdictions. The actual purchasing focus covers emergency-response medications (naloxone), generic pharmaceutical products across multiple therapeutic categories, OTC items, and pharmaceutical supply-chain relationships with wholesalers and manufacturers.

Seminole County, Florida and Texas Health and Human Services Commission are the standout recent issuers, with MMCAP representing a multi-state cooperative vehicle administered by the Minnesota Department of Administration. Seminole County issued an IFB (Solicitation IFB60459723LAS) posted June 30, 2026 with response due July 26, 2023 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. Texas HHS posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements. MMCAP released an RFP (S1070000015802) on January 20, 2026 with response due March 26, 2026 to establish manufacturer contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with contracts effective July 1, 2026. The code shows activity concentrated in the Southeast and Upper Midwest, though the MMCAP cooperative vehicle signals participation spanning multiple states. Given the mismatch between the code's nominal rupatadine scope and the actual pharmaceutical procurement being solicited, this code may show limited relevant activity for vendors focused specifically on rupatadine supply.